Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “buy” rating reissued by equities researchers at Royal Bank of Canada in a note issued to investors on Wednesday, March 14th. They presently have a $91.00 target price on the biotechnology company’s stock. Royal Bank of Canada’s price objective indicates a potential upside of 26.85% from the company’s previous close.
A number of other research firms have also recently weighed in on SRPT. JPMorgan Chase boosted their target price on shares of Sarepta Therapeutics from $75.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 14th. Credit Suisse Group boosted their price objective on shares of Sarepta Therapeutics from $81.00 to $100.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 13th. Leerink Swann reaffirmed a “positive” rating and set a $92.00 price target (up previously from $79.00) on shares of Sarepta Therapeutics in a research report on Tuesday, March 13th. HC Wainwright upped their price objective on shares of Sarepta Therapeutics from $75.00 to $92.00 and gave the company a “buy” rating in a report on Monday, March 12th. Finally, Piper Jaffray restated an “overweight” rating and issued a $76.12 target price (down previously from $83.00) on shares of Sarepta Therapeutics in a report on Monday, March 12th. Five investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $76.40.
Sarepta Therapeutics stock traded down $1.12 during midday trading on Wednesday, reaching $71.74. 759,523 shares of the company’s stock were exchanged, compared to its average volume of 1,565,732. The company has a debt-to-equity ratio of 0.54, a quick ratio of 12.96 and a current ratio of 13.91. The stock has a market capitalization of $4,805.80, a P/E ratio of -43.74 and a beta of 1.29. Sarepta Therapeutics has a 52 week low of $28.14 and a 52 week high of $84.37.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. The business had revenue of $57.30 million during the quarter, compared to analyst estimates of $57.33 million. During the same quarter in the previous year, the firm posted ($0.71) earnings per share. The firm’s quarterly revenue was up 961.1% on a year-over-year basis. research analysts forecast that Sarepta Therapeutics will post -1.18 earnings per share for the current year.
A number of large investors have recently bought and sold shares of the stock. Benchmark Capital Advisors boosted its stake in Sarepta Therapeutics by 4.2% during the fourth quarter. Benchmark Capital Advisors now owns 21,250 shares of the biotechnology company’s stock worth $1,182,000 after acquiring an additional 850 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Sarepta Therapeutics by 39.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock worth $192,000 after buying an additional 977 shares during the last quarter. US Bancorp DE raised its holdings in Sarepta Therapeutics by 35.0% in the fourth quarter. US Bancorp DE now owns 4,224 shares of the biotechnology company’s stock worth $235,000 after buying an additional 1,095 shares during the last quarter. Bank of Montreal Can raised its holdings in Sarepta Therapeutics by 1.3% in the fourth quarter. Bank of Montreal Can now owns 85,707 shares of the biotechnology company’s stock worth $4,770,000 after buying an additional 1,103 shares during the last quarter. Finally, Shepherd Financial Partners LLC raised its holdings in shares of Sarepta Therapeutics by 16.1% during the fourth quarter. Shepherd Financial Partners LLC now owns 9,673 shares of the biotechnology company’s stock valued at $539,000 after purchasing an additional 1,340 shares during the last quarter. 84.98% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/royal-bank-of-canada-reaffirms-buy-rating-for-sarepta-therapeutics-srpt.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.